Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRA: AZD5305 alone or with camizestrant in advanced solid tumors
jRCT2031210609Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Open-label trial of saruparib and camizestrant in Nonhematologic neoplasms (2 arms), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events and serious adverse events and Number of subjects with dose-limiting toxicity. Started Feb 2022; status: recruiting.
02
Drugs
saruparibcamizestrant
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210609.